Acalabrutinib Safety Study for Leukemia Patients With Heart Impairment

Who can take part

• Men and women ≥ 18 years of age, at the time of signing the informed consent
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3
• Meet at least one of the following cardiovascular inclusion criteria: (a) Left ventricular ejection fraction (LVEF) < 50% as assessed by local ECHO at screening. (b) History of heart failure or meeting Universal Definition of Heart Failure at screening (Appendix M), regardless of current LVEF. (c) History of ischaemic heart disease (IHD) including acute coronary syndrome, myocardial infarction, or coronary revascularization (percutaneous coronary intervention/stent or coronary artery bypass surgery). (d) Diagnosis of cardiomyopathy. (e) Ongoing clinically significant (symptomatic or requiring intervention) cardiac arrhythmia, including atrial fibrillation or other arrhythmias. (f) History of moderate or severe cardiac valvular diseases as documented per cardiac imaging
• Diagnosis of CLL per (Hallek et al, 2018)
• Treatment naïve (TN) or relapsed/refractory (R/R) patients who have received no more than 2 prior lines of systemic anti-CLL treatment
• Active disease per iwCLL 2018 (Hallek et al, 2018) criteria that requires treatment
• Meet the following laboratory parameters: - Absolute neutrophil count (ANC) ≥ 500 cells/μL (0.50 × 109/L). - Platelet count ≥ 30,000 cells/μL (30 × 109/L). - Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 × upper limit of normal (ULN). - Total bilirubin ≤ 1.5 × ULN, unless directly attributable to Gilbert’s syndrome. - Estimated creatinine clearance (ie, estimated glomerular filtration rate [eGFR] using Cockcroft-Gault) ≥ 40 mL/min, or serum creatinine ≤ 2 x ULN
• Women and men who are sexually active and can bear children must agree to use highly effective forms of contraception. Contraceptives used by men or women should follow the respective Prescribing Information requirements and be consistent with local regulations
• Patients must be willing and able to adhere to the study visit schedule, understand, and comply with other protocol requirements, and provide written informed consent and authorisation to use protected health information (in accordance with national and local patient privacy regulations). Note: vulnerable patients, as defined in the International Council for Harmonisation (ICH) Good Clinical Practice (GCP), are not allowed on this protocol (eg, prisoners or institutionalised patients)

Who cannot take part

• Known active central nervous system (CNS) leukaemia, leptomeningeal disease or spinal cord compression. In case of R/R patients with prior history of CNS localisation of leukaemia who received treatment are eligible provided that there is no evidence of CNS involvement at study entry as documented by CSF cytology and/or brain MRI
• Concurrent participation in another therapeutic clinical trial
• Prior exposure to a BTKi
• Major surgery within 30 days before first dose of study treatment
• Received any investigational drug within 30 days or 5-half-lives (whichever is shorter) before first dose of study treatment
• Received a live virus vaccination within 28 days of first dose of study treatment
• History of stroke or intracranial haemorrhage within 6 months prior to randomisation
• Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists (eg, phenprocoumon) within 7 days of first dose of study treatment. Direct anti-X (DOACs) or low molecular weight heparins (LMWH, eg, enoxaparin) on stable dosing schedule is allowed
• Requires treatment with a strong cytochrome P450 3A (CYP3A) inhibitor/inducer. The use of strong CYP3A inhibitors within 1 week or strong CYP3A inducers within 3 weeks of the first dose of study treatment is prohibited
• Uncontrolled hypertension (> 140/90 mmHg) despite optimal management
• Current life-threatening illness, medical conditions, organ system dysfunction or lifestyle habits which, in the investigator’s opinion, could compromise the patient’s safety or ability to adhere to the study protocol
• Unable to swallow tablets or malabsorption syndrome, or disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or gastric bypass, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction
• History of or ongoing confirmed progressive multifocal leukoencephalopathy (PML)
• History of prior malignancy except for the following: - Prior history of malignancy with no evidence of active disease present for more than 3 years before screening or felt to be at low risk for recurrence by the treating physician. - Adequately treated lentigo maligna melanoma without current evidence of disease or adequately resected non-melanomatous skin cancer (ie, basal cell carcinoma or squamous cell carcinoma of the skin). - Curatively treated in situ carcinoma of the cervix or carcinoma in situ of the prostate at any time prior to study without current evidence of disease
• Hypersensitivity to the study treatments active substance or to any of the excipients listed in the Prescribing Information
• Active uncontrolled systemic infection (bacterial, fungal, viral, or other) or clinically significant localised infection
• Known history of infection with human immunodeficiency virus (HIV)
• Serologic status reflecting active HepB or HepC infection.Patients who are hepatitis B core antibody (anti-HBc) positive and who are hepatitis B surface antigen (HBsAg) negative will need to have a negative DNA polymerase chain reaction (PCR) result before randomisation and must be willing to undergo DNA PCR testing during the study. Those who are HBsAg-positive or hepatitis B PCR positive will be excluded. Patients who are hepatitis C antibody positive will need to have a negative RNA PCR result before randomisation. Those who are hepatitis C PCR positive will be excluded
• History of bleeding diathesis (eg, haemophilia, von Willebrand disease)
• Uncontrolled cardiac/cardiovascular disease including the following: (a) Baseline cardiac troponin (cTnI or cTnT or hs-cTn) levels greater than the upper limit of normal (per the local laboratories reference range) that is due to an acute coronary event and cannot be fully explained by non-ischaemic conditions. (b) Uncontrolled cardiac tachyarrhythmias (sinus, atrial or ventricular) that require new/additional therapy within the last month. (c) Clinically significant QT prolongation defined as QT interval corrected by Fridericia’s formula (QTcF) values; QTcF > 500 ms. (d) Any of the following within the last 3 months: i. Unstable IHD: percutaneous coronary intervention, coronary artery bypass surgery, or an episode of acute coronary syndrome including acute myocardial infarction and unstable angina pectoris. ii. Major cardiac surgery/procedures or valvular surgery. iii. Hospitalization due to heart failure
• Breastfeeding or pregnant
• Ongoing Richter’s transformation
• Uncontrolled haemolytic anaemia
• Any contraindication to the study treatments in Arm B as per the local Prescribing Information